Periorbital muscle atrophy associated with topical bimatoprost therapy

Priscilla Xinhui Wang
Victor Teck Chang Koh
Jin Fong Cheng
Department of Ophthalmology, National University Health System, Singapore

Abstract: Topical Bimatoprost is a common and popular prostaglandin analog used as an ocular hypotensive agent in the treatment of glaucoma. Side effects include ocular hyperaemia, ocular pruritus, and periorcular and iris pigmentary changes. Periorbital lipodystrophy is another well-documented outcome associated with chronic use of topical bimatoprost, which results in periorbital hallowing, upper eyelid sulcus deepening, eyelid retraction and enophthalmos. We report an unusual case of periorbital muscle atrophy and weakness from unilateral topical bimatoprost use. Our patient had primary angle closure and experienced a right upper eyelid ptosis 2 months after she started to use topical bimatoprost in that eye. Clinical measurements of her eyelids clearly showed reduction in the function of her right levator muscle, suggesting that effects of topical bimatoprost may not be limited to periorbital fat. She was advised to stop topical bimatoprost and right ptosis correction surgery with levator muscle advancement was performed successfully. Ophthalmologists and patients should be aware of this potential rare side effect of topical bimatoprost, as it may be potentially disfiguring, especially with monocular use. However, its exact mechanism of action needs to be clarified further.

Keywords: prostaglandin analog, levator, muscle atrophy, muscle weakness, ptosis, side effects

Introduction
Topical bimatoprost is a popular prostaglandin analog used primarily as a powerful ocular hypotensive agent for treatment of glaucoma (approved in 2001). It is also used cosmetically to induce hypertrichosis, approved by the US Food and Drug Administration in 2008 as Latisse (Allergan, Inc, Irvine, CA, USA). However, it may cause complications such as periorcular skin hyperpigmentation, intraocular inflammation, and conjunctival hyperemia. These mainly affect superficial tissues and, to date, there has been no report on involvement of deeper periorbital tissues as far as we are aware. Herein, we report an unusual case of periorbital muscle atrophy and weakness secondary to unilateral topical bimatoprost use.

Case report
A 58-year-old Chinese female was referred to the oculoplastics services of National University Hospital, Singapore, for right upper eyelid ptosis of 1.5 years’ duration and difficulty in closing her right eye. She had a history of bilateral primary angle closure diagnosed in 2003, for which bilateral laser peripheral iridotomies were performed. She was started on topical latanoprost 0.005% once every night to the right eye, as intraocular pressure (IOP) was suboptimal. Subsequently, she underwent an uneventful right cataract extraction with intraocular lens implantation that same year. As IOP
remained optimal postoperatively, she was taken off topical
latanoprost. Her condition remained stable until 2008 when
there were progressive defects in her right visual field with
increased IOP. Thus, she was started on topical bimatoprost
0.03% (Lumigan, Allergan, Inc) once every night to her
right eye.

On review after 3 months, IOP was found to have been
controlled adequately. However, she reported an onset of
right upper eyelid drooping 2 months after starting treat-
ment. There was no history of trauma or eyelid surgery. The
ptosis did not show any diurnal variability or fatigability, and
there was no diplopia. A detailed evaluation by the neuro-
ophthalmology team revealed no underlying neurological
cause. Four months after starting treatment, the treated eye
was found to have long eyelashes and ocular pigmentation.
Subsequently, the patient reported worsening of her right
ptosis after 12 months on treatment and was keen for referral
to the oculoplastics team.

By the time the patient was reviewed by the oculoplastics
team in 2010, her right upper eyelid ptosis had persisted for
1.5 years. Measurements of the palpebral aperture (PA) of
her right and left eye were 6 mm and 8 mm, respectively.
Measurements of marginal reflex distance 1 (MRD1) for
her right and left eyes were 0.5 mm and 2 mm, respectively.
Levator palpebrae function was 8 mm for the right eye and 14
mm for the left eye. Lid creases measured 7 mm and 5 mm
for the right and left eye, respectively.

Eventually, the patient underwent a surgical correction
of her ptosis with levator muscle advancement in August
2011. Surgery was uncomplicated and postoperative recovery
was uneventful. Seven months after the operation, her PA
measured 9 mm and 8 mm while MRD1 measured 4 mm and
3 mm for the right and left eye, respectively.

The pre- and postoperative clinical photos of her eyelids are
shown in Figures 1 and 2, respectively. Preoperatively, she had
clinically significant right ptosis obscuring her visual axis, and
right epiphora with oribicularis oculi muscle weakness.

**Discussion**

Topical bimatoprost is highly efficacious and superior to
many other anti-glaucoma eye drops. However, it com-
monly causes side effects such as ocular hyperemia, perio-
ercular and iris pigmentary changes, although these are mostly
reversible with cessation of use. Periorbital lipodystrophy
resulting in periorbital hollowing, eyelid retraction, and
enophthalmos from chronic use of bimatoprost has also been
well-documented. Upper eyelid sulcus deepening has been
shown to occur significantly more frequently (objectively
and subjectively) with bimatoprost use than with other
prostaglandin analogs, namely latanoprost, tafluprost, and
unoprostone. Aihara et al reported an increased incidence of
upper eyelid sulcus deepening in patients who were switched
from latanoprost to bimatoprost, suggesting that the latter
has a more potent effect on periorbital fat tissue. The term
“prostaglandin-associated periorbitopathy” (PAP) has been
coined to describe the constellation of periorbital soft-tissue
changes resulting from the use of topical prostaglandin
analogos. The clinical features of PAP include upper eyelid
ptosis, deepening of the upper eyelid sulcus, involution of
dermatochalasis, orbital fat atrophy, mild enophthalmos, flatt-
tening of lower eyelid bags, inferior scleral show, and tight
orbits. These effects can appear after a period of several
weeks to several years, and have been reported to be reversible
upon cessation of use. Most of the anatomical changes in
PAP are thought to be caused by orbital fat atrophy, while
dehiscence of levator aponeurosis may account for the upper lid ptosis.

It has been postulated that upregulation of prostaglan-
din F2-α results in significant anti-adipogenic effect. Prostaglandin F2-α blocks adipogenesis through the activa-
tion of mitogen-activated protein kinase, resulting in
the inhibitory phosphorylation of peroxisome proliferator-
activated receptor-gamma, a nuclear hormone receptor
central to adipocyte differentiation. Topical prostaglandin
analogos have been shown to downregulate the expression

![Figure 1 Preoperative clinical photo of patient’s eyelids.](https://www.dovepress.com/)

![Figure 2 Postoperative clinical photo of patient’s eyelids.](https://www.dovepress.com/)
of peroxisome proliferator-activated receptor-gamma and inhibit the accumulation of intracytoplasmic lipid droplets. The reversal of fat atrophy upon cessation of use may be due to removal of this inhibition, allowing adipogenesis to recommence. Imaging of orbits (computed tomography and magnetic resonance imaging) has ruled out orbital pathology in the fellow eye (resulting in pseudo-enophthalmos) and other disease processes such as cicatrizing changes. Periorbital changes may be underestimated, as they may be subtle or attributed to age-related volume depletion. Bilateral topical use of prostaglandin analog eye drops in glaucoma may lead to equivocal changes in both eyes, which may be less obvious and thus under-reported. However, in Asians, who tend to have greater upper eyelid fullness, unilateral periorbital fat atrophy may result in more obvious disfigurement.

To date, as far as we are aware, there has been no report of topical bimatoprost use resulting in periorbital muscle atrophy. Our patient developed ptosis after 2 months of topical bimatoprost use. In Figure 1, it can also be seen that the patient had deepening of her upper eyelid sulcus and dermatochalasis involution. Clinical eyelid measurements clearly showed reduced function of the right upper eyelid, suggesting that the effects of topical bimatoprost may not be limited to periorbital fat. Reduced levator function and ptosis may be masked by the more common eyelid retraction and deepening of the upper eyelid sulcus. Peplinski and Albiani Smith postulated that Müller muscle (smooth muscle) may be directly affected by prostaglandin-mediated pathways, but whether there is a similar effect on levator muscle (striated muscle) remains unknown. Other reasons for the induced right ptosis might have been stretching of the eyelid due to initiation of glaucoma-drop usage, disruption of the Whitnall’s suspensory ligament from the relative enophthalmos, or the patient’s previous cataract surgery, even though there was no fixing of patient’s superior rectus during the surgery. Further studies are warranted. In this case, the patient was advised to stop topical bimatoprost and right ptosis correction surgery was performed successfully. In Figure 2, it can be seen that the upper eyelid sulcus deepening was much reduced, with a marked improvement in the dermatochalasis involution after the surgery. The patient was happy and satisfied that she did not have ptosis anymore. It may be worthwhile to note that topical bimatoprost used cosmetically can also cause unwanted side effects such as conjunctival hyperemia and IOP reduction. Therefore, while considered generally safe when applied superficially to the base of eyelashes, ocular side effects can still occur with risk ofinstillation onto the eye surface.

Conclusion

Herein, we report an unusual and previously unreported case of upper eyelid ptosis secondary to levator muscle atrophy as a result of the chronic unilateral use of topical bimatoprost. Clinicians and patients should be aware of this, as it may compromise visual field and be potentially disfiguring, especially when used monocularly. Patients using Latisse should similarly be warned, since the cosmetic and ophthalmic preparations are identical. Patients should be carefully monitored upon initiating treatment. Although this side effect may not be completely reversible with discontinuation of medication, this case shows that it may be successfully corrected with surgical intervention. However, its exact mechanism of action needs to be clarified further.

Disclosure

The authors declare no conflicts of interest in this work. This report received no funding/support.

References


